Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Edi Pharmaceuticals: Dolutegravir Sodium Tablets Approved for Drug Registration
People’s Financial News, March 15 — Aidi Pharmaceuticals (688488) announced on March 15 that the company has received the “Drug Registration Certificate” for Dolutegravir Sodium Tablets, approved and issued by the National Medical Products Administration on March 10. Approved indications: in combination with other antiretroviral drugs, for the treatment of HIV-infected adults and children aged 12 and above.